
https://www.science.org/content/blog-post/new-old-antibiotic
# A New Old Antibiotic (May 2015)

## 1. SUMMARY

The article discusses Symbiomix, a small biotechnology company that entered Phase III trials in 2015 with secnidazole, a nitroimidazole antibiotic that had been used generically in other countries for decades but was never approved by the FDA in the United States. The company was pursuing a strategy the author describes as "regulatory arbitrage"â€”taking advantage of an existing, well-established drug from international markets and seeking FDA approval to market it as a new drug in the US with premium pricing.

The purported advantage of secnidazole for treating bacterial vaginosis was its single-dose administration compared to longer treatment courses of existing alternatives like metronidazole. The author notes that the Phase III trial is essentially a formality since the drug's safety and efficacy were already well-established through decades of international use. The key business challenge identified is whether payers will view the convenience advantage as worth the premium pricing for what is essentially a repurposed generic drug.

## 2. HISTORY

In August 2017, the FDA **approved secnidazole** (marketed as **Solosec**) for the treatment of bacterial vaginosis in adult women. The approval was based on the Phase III trial referenced in the article, which demonstrated efficacy with a single oral dose.

The commercial outcome was mixed. Secni


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150506-new-old-antibiotic.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_